Stomach Neoplasms

• 

  Subject Areas on Research

  • 'Signet-ring' cell gastric adenocarcinoma metastatic to a neurogenous hyperplasia of the appendix. 
  • A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. 
  • A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen. 
  • A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk. 
  • A Review of Sleeve Gastrectomy Specimen Histopathology. 
  • A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiated-Type Intramucosal Gastric Cancer. 
  • A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer. 
  • A Summary of the 2020 Gastric Cancer Summit at Stanford University. 
  • A cohort analysis of U.S. stomach cancer mortality 1950-1977. 
  • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. 
  • A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. 
  • A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A pilot study of preoperative chemoradiation for gastric cancer. 
  • A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. 
  • A stochastic compartment model of stomach cancer with correlated waiting time distributions. 
  • ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. 
  • AGA Institute Quality Measure Development for the Management of Gastric Intestinal Metaplasia With Helicobacter pylori. 
  • ASO Visual Abstract: Patterns and Impact of Fragmented Care in Stages II and III Gastric Cancer. 
  • Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma. 
  • Acceptance of repeat esophagogastroduodenoscopy to detect gastric cancer in a Chinese immigrant cohort. 
  • Adenocarcinoma of the stomach. Changing patterns over the last 4 decades. 
  • Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. 
  • An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. 
  • An improved method for bivariate meta-analysis when within-study correlations are unknown. 
  • An integrative approach identified genes associated with drug response in gastric cancer. 
  • An unexpected intraoperative finding. 
  • Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. 
  • Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. 
  • Assessment of advanced gastric cancer management in the United States. 
  • Assessment of spatial variation of risks in small populations. 
  • Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck. 
  • Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults. 
  • Association of Helicobacter pylori and Autoimmune Gastritis With Stomach Cancer in a Cohort of Young Finnish Women. 
  • Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case-control study in Hawaii. 
  • Associations of genotypes and haplotypes of IL-17 with risk of gastric cancer in an eastern Chinese population. 
  • Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. 
  • Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. 
  • Benign gastric ulcer masquerading as a submucosal tumor. 
  • CD44-SLC1A2 gene fusions in gastric cancer. 
  • CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables. 
  • Cancer Progress and Priorities: Gastric Cancer. 
  • Carcinoids associated with multiple endocrine neoplasia syndromes. 
  • Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. 
  • Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling. 
  • Changing trends in the proportions of small (≤ 2 cm) proximal and non-proximal gastric carcinomas treated at a high-volume tertiary medical center in China. 
  • Cimetidine and gastric carcinoma. 
  • Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. 
  • Circulating cytokines and gastric cancer risk. 
  • Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. 
  • Clinico-pathologic conference: 12-year-old girl with fatigue, anemia, weight loss, abdominal distention, and occasional nausea and vomiting. 
  • Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Lauren's Classification. 
  • Comment on "Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment". 
  • Common and Co-Occurring Symptoms Experienced by Patients With Gastric Cancer. 
  • Compartment model approach to the estimation of tumor incidence and growth: investigation of a model of cancer latency. 
  • Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. 
  • Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. 
  • Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. 
  • Comprehensive molecular characterization of gastric adenocarcinoma. 
  • Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation. 
  • Computed tomography of the gastroesophageal junction: value of the left lateral decubitus view. 
  • Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: a multi-institutional analysis of 502 patients. 
  • Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan. 
  • Controlling Gastric Cancer in a World of Heterogeneous Risk. 
  • Data Set for Reporting Carcinoma of the Stomach in Gastrectomy. 
  • Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. 
  • Deep learning-based AI model for signet-ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer. 
  • Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. 
  • Defining surgical indications for type I gastric carcinoid tumor. 
  • Development, validation, and evaluation of a risk assessment tool for personalized screening of gastric cancer in Chinese populations. 
  • Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. 
  • Diabetic biomarkers and the risk of proximal or distal gastric cancer. 
  • Diagnostic challenges of intra-operative frozen consultation for gastrointestinal signet ring cell carcinoma†. 
  • Diet, Helicobacter pylori strain-specific infection, and gastric cancer risk among Chinese men. 
  • Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. 
  • Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. 
  • Does the interval of screening endoscopy affect survival in gastric cancer patients?: A cross-sectional study. 
  • E-cadherin in gastric carcinomas: Relations with histological parameters and its prognostic value. 
  • EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance? 
  • ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. 
  • ERCC1 and ERCC2 variants predict survival in gastric cancer patients. 
  • Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. 
  • Endogenous glucocorticoids prevent gastric metaplasia by suppressing spontaneous inflammation. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. 
  • Epstein-Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia. 
  • Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. 
  • Esophageal and esophagogastric junction cancers, version 1.2015. 
  • Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. 
  • Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. 
  • FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. 
  • FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. 
  • Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma. 
  • Feeding jejunostomy tube placement during resection of gastric cancers. 
  • First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. 
  • Flow cytometry as a predictive indicator in patients with operable gastric cancer. 
  • Foregut carcinoids: a clinical and biochemical analysis. 
  • Fruit and vegetable consumption and risk of distal gastric cancer in the Shanghai Women's and Men's Health studies. 
  • Fruit and vegetable consumption, Helicobacter pylori antibodies, and gastric cancer risk: A pooled analysis of prospective studies in China, Japan, and Korea. 
  • Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression. 
  • Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. 
  • Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. 
  • Gastric adenocarcinoma associated with gastritis cystica profunda in an unoperated stomach. 
  • Gastric adenocarcinoma: CT versus surgical staging. 
  • Gastric cancer pharmacogenetics: progress or old tripe? 
  • Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. 
  • Gastric cancer-molecular and clinical dimensions. 
  • Gastric cancer. 
  • Gastric cancer. Clinical practice guidelines in oncology. 
  • Gastric cancer: an infectious disease. 
  • Gastric carcinoma after gastrojejunostomy for benign disease: radiographic findings. 
  • Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting. 
  • Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. 
  • Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. 
  • Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: 177Lu-DOTATATE. 
  • Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. 
  • Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library. 
  • Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. 
  • Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. 
  • Genetic variant of PRKAA1 and gastric cancer risk in an eastern Chinese population. 
  • Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population. 
  • Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population. 
  • Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. 
  • Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. 
  • Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. 
  • Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. 
  • Helicobacter pylori Blood Biomarkers and Gastric Cancer Survival in China. 
  • Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. 
  • Helicobacter pylori prevalence and circulating micronutrient levels in a low-income United States population. 
  • Helicobacter pylori stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and -independent ERK activation. 
  • High rates of advanced gastric cancer in community of Flushing, New York. 
  • Highly recurrent CBS epimutations in gastric cancer CpG island methylator phenotypes and inflammation. 
  • Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. 
  • Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. 
  • Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 
  • How do global trends in Helicobacter pylori prevalence inform prevention planning? 
  • Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. 
  • IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. 
  • Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. 
  • Identification and functional characterization of JWA polymorphisms and their association with risk of gastric cancer and esophageal squamous cell carcinoma in a Chinese population. 
  • Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. 
  • Immunostimulatory membrane proteins potentiate H. pylori-induced carcinogenesis by enabling CagA translocation. 
  • Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma. 
  • Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. 
  • Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. 
  • Intake of specific nonfermented soy foods may be inversely associated with risk of distal gastric cancer in a Chinese population. 
  • Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. 
  • Integrated genomic characterization of oesophageal carcinoma. 
  • Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. 
  • Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. 
  • Interleukin-1B gene promoter variants are associated with an increased risk of gastric cancer in a Chinese population. 
  • Internal hernia after gastrectomy for cancer with Roux-Y reconstruction. 
  • Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. 
  • Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients? 
  • Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. 
  • Laparoscopic Total Gastrectomy in the Western Patient Population: Tips, Techniques, and Evidence-based Practice. 
  • Laparoscopic versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a systematic review. 
  • Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. 
  • Leiomyoma involving the gastrocolic ligament: CT demonstration. 
  • Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. 
  • Lymphoepithelioma-like carcinoma: a distinct type of gastric cancer. 
  • MDM4 genetic variants and risk of gastric cancer in an Eastern Chinese population. 
  • Malignant gastric outlet obstruction: bridging another divide. 
  • Mantle zone lymphoma in a gastric glomus tumor. 
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. 
  • Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. 
  • Methylation subtypes and large-scale epigenetic alterations in gastric cancer. 
  • Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. 
  • Minimally invasive gastrectomy for gastric cancer: A national perspective on oncologic outcomes and overall survival. 
  • Minimizing operative time for robotic gastrectomy in cancer: analysis of the major factors for four detailed steps. 
  • Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. 
  • Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. 
  • Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. 
  • Need for clarification of data in the recent meta-analysis about p53 polymorphism and gastric cancer risk. 
  • Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. 
  • No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. 
  • Nomogram to predict lymph node metastasis in patients with early gastric cancer: a useful clinical tool to reduce gastrectomy after endoscopic resection. 
  • Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. 
  • Oncogenic pathway combinations predict clinical prognosis in gastric cancer. 
  • P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. 
  • PET/Computed Tomography and Precision Medicine: Gastric Cancer. 
  • PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population. 
  • Paradoxical relationship between chromosomal instability and survival outcome in cancer. 
  • Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. 
  • Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer. 
  • Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. 
  • Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. 
  • Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). 
  • Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). 
  • Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. 
  • Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach. 
  • Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. 
  • Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. 
  • Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. 
  • Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. 
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. 
  • Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. 
  • Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population. 
  • Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. 
  • Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. 
  • Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population. 
  • Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. 
  • Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. 
  • Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions associated with risk of gastric cancer in South China: a case-control analysis. 
  • Population-based cohort studies of type 2 diabetes and stomach cancer risk in Chinese men and women. 
  • Potentially functional polymorphisms in the CASP7 gene contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. 
  • Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. 
  • Potentially functional variants of PLCE1 identified by GWASs contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. 
  • Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. 
  • Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG. 
  • Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). 
  • Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. 
  • Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. 
  • Preoperative chemoradiotherapy for locally advanced gastric cancer. 
  • Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered? 
  • Prevalence of deleterious ATM germline mutations in gastric cancer patients. 
  • Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. 
  • Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. 
  • Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. 
  • Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. 
  • Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. 
  • Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). 
  • Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. 
  • Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. 
  • Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. 
  • Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. 
  • Results of radiation therapy in gastric cancer. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Rt-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. 
  • S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. 
  • STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. 
  • Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. 
  • Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. 
  • Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. 
  • Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. 
  • Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data. 
  • Simultaneous detection of the tumor suppressor FHIT gene and protein using the multi-functional biochip. 
  • Smoking, Helicobacter Pylori Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea. 
  • Solid tumor second primary neoplasms: who is at risk, what can we do? 
  • Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 
  • Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. 
  • Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma. 
  • Sporadic gastric carcinoid tumor laparoscopically resected: a case report. 
  • Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis. 
  • Subacute headache in a patient with metastatic gastric cancer. 
  • Submucosal resection of giant gastric lipoma. 
  • Symptom experience and self-management for multiple co-occurring symptoms in patients with gastric cancer: A qualitative study. 
  • Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 
  • Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. 
  • Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. 
  • TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. 
  • TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). 
  • Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. 
  • Technical considerations in radiation therapy for gastroesophageal junction cancer. 
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. 
  • The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. 
  • The Durham Initiative for Stomach Health (DISH): a pilot community-based Helicobacter pylori education and screening study. 
  • The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer. 
  • The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis. 
  • The U-shaped association between body mass index and gastric cancer risk in the Helicobacter pylori Biomarker Cohort Consortium: A nested case-control study from eight East Asian cohort studies. 
  • The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. 
  • The association between gestational diabetes mellitus and cancer in women: A systematic review and meta-analysis of observational studies. 
  • The association of cigarette smoking with gastric cancer: the multiethnic cohort study. 
  • The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. 
  • The expression of Claudin-4 in gastric cancer tissue: A single center experience. 
  • The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. 
  • The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. 
  • The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. 
  • The use of mortality time series data to produce hypothetical morbidity distributions and projects mortality trends. 
  • Towards a tailored lymphadenectomy for gastric cancer based on the correlation between the primary tumor location and the first lymphatic drain basin: Preliminary data. 
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. 
  • Utility of a prognostic nomogram designed for gastric cancer in predicting outcome of patients with R0 resected duodenal adenocarcinoma. 
  • Validation of a Blood Biomarker for Identification of Individuals at High Risk for Gastric Cancer. 
  • Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. 
  • Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. 
  • Whole-genome reconstruction and mutational signatures in gastric cancer. 
  • Wnt proteins synergize to activate β-catenin signaling. 
  • [Diagnosis of early gastric marginal zone lymphoma (MALT lymphoma) in endoscopic biopsies. Report of a case that demonstrates the utility of immunohistochemistry and the molecular analysis.]. 
  • [Variation of mortality risk among cancer patients and individualized therapy]. 
• 

  Keywords of People

  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics